Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy
Open accessAbstract
Background: Accumulation of cortical and subcortical tau pathology is the primary pathological substrate for progressive supranuclear palsy (PSP). 18 F‐AV‐1451, a radiotracer that binds to the pathological tau protein, may be helpful for in vivo visualization and quantitation of tau pathology in PSP. Objectives: The objectives of this study were to investigate cortical and subcortical 18 F‐AV‐1451 binding patterns in patients with PSP. Methods: We recruited 14 PSP patients and compared their cortical and subcortical binding patterns in 18 F‐AV‐1451 positron emission tomography (PET) studies with those of 15 Parkinson's disease (PD) patients and 15 healthy controls. Results: In both the PD and PSP groups, subcortical 18 F‐AV‐1451 binding did not correlate with the severity of motor dysfunctions, and cortical binding did not differ between the controls and each patient group. However, the PSP patients showed greater 18 F‐AV‐1451 binding in the putamen, globus pallidus, subthalamic nucleus, and dentate nucleus when compared with the controls, whereas the PD patients showed lower 18 F‐AV‐1451 binding in the substantia nigra than controls. Conclusions: The PSP and PD patients showed distinct subcortical 18 F‐AV‐1451 binding patterns reflecting subcortical tau pathology in PSP and reduced nigral neuromelanin in PD. However, there was no correlation with the severity of motor dysfunction, no cortical regions with increased binding in PSP patients, and variable degrees of subcortical binding even in the controls. Therefore, the 18 F‐AV‐1451 PET may be less than ideal for assessing tau pathology in PSP. Further studies will be required to validate the clinical correlation and to understand the clinical utility of 18 F‐AV‐1451 PET for PSP patients. © 2016 International Parkinson and Movement Disorder Society
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Earlier PET investigations have detected alterations in PSP with ligands for tau and for microglial activation.
“Previous positron emission tomography (PET) has indicated changes in PSP using ligands targeting tau8–16 and microglial activation17,18.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [9]
Only a few previous studies have explored how [11C]PK11195 and [18F]AV-1451 binding relate to disease severity in PSP.
“This finding adds relevant information to the literature as only a few previous studies have explored how [11C]PK11195 and [18F]AV-1451 binding relate to disease severity in PSP8,9,13,14,16,18.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [9]
In PSP, higher [18F]AV-1451 binding is found in subcortical rather than cortical regions, consistent with the known distribution of PSP-Richardson's syndrome.
“In PSP, higher [18F]AV-1451 binding has been found in sub-cortical rather than cortical regions (the reverse for AD), consistent with the well-established cortical versus sub-cortical distribution of PSP-Richardson’s syndrome8–10,13,14,16.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [9]
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · see citing works
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610 · see citing works
A fast diffeomorphic image registration algorithm
Ashburner, J. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.07.007 · Cited by 8,122 · see citing works
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653 · see citing works
Automatically Parcellating the Human Cerebral Cortex
Fischl, B. R. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg087 · Cited by 4,208 · see citing works
Williams, D. R., de Silva, R., Paviour, D. C., Pittman, A. M., Watt, H., Kilford, L., Holton, J. L., Révész, T., & Lees, A. J. (2005) · Brain · doi:10.1093/brain/awh488 · Cited by 733 · see citing works
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650 · see citing works
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615 · see citing works
A clinical rating scale for progressive supranuclear palsy
Golbe, L. I., & Ohman‐Strickland, P. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614 · see citing works
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
Compta, Y., Parkkinen, L., O’Sullivan, S. S., Vandrovcová, J., Holton, J. L., Collins, C., Lashley, T., Kallis, C., Williams, D. R., de Silva, R., et al. (2011) · Brain · doi:10.1093/brain/awr031 · Cited by 585 · see citing works
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · see citing works
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499 · see citing works
Self-citationWilliams, D. R., Holton, J. L., Strand, C., Pittman, A. M., de Silva, R., Lees, A. J., & Révész, T. (2007) · Brain · doi:10.1093/brain/awm104 · Cited by 415 · see citing works
Litvan, I., Agid, Y., Jankovic, J. J., Goetz, C. G., Brandel, J., Lai, E. C., Wenning, G. K., D'Olhaberriague, L., Verny, M., Chaudhuri, К. R., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.922 · Cited by 347 · see citing works
Tau PET in Alzheimer disease and mild cognitive impairment
Cho, H., Choi, J. Y., Hwang, M. S., Lee, J., Kim, Y. J., Lee, H., Lyoo, C. H., Ryu, Y. H., & Lee, M. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002892 · Cited by 267 · see citing works
Self-citationQuantifying inter-individual anatomical variability in the subcortex using 7 T structural MRI
Keuken, M. C., Bazin, P., Crown, L., Hootsmans, J., Laufer, A., Müller-Axt, C., Sier, R., van der Putten, E. J., Schäfer, A., Turner, R., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.03.032 · Cited by 223 · see citing works
Wills, J., Jones, J. M., Haggerty, T., Duka, V., Joyce, J. N., & Sidhu, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.06.017 · Cited by 211 · see citing works
Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging
Ohtsuka, C., Sasaki, M., Konno, K., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.04.005 · Cited by 154 · see citing works
<i>In vivo</i>imaging of neuromelanin in Parkinson’s disease using<sup>18</sup>F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128 · see citing works
PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy
Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F. C., Mazziotta, J. C., Mendez, M. F., Donoghue, N., Small, G. W., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130032 · Cited by 106 · see citing works
Kim, J. S., Cho, H., Choi, J. Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132585 · Cited by 41 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485 · see citing works
Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175 · see citing works
Hall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132 · see citing works
Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case.
Marquié, M., Verwer, E. E., Meltzer, A. C., Kim, S. J. W., Agüero, C., Gonzalez, J., Makaretz, S. J., Siao Tick Chong, M., Ramanan, P., Amaral, A. C., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0482-0 · Cited by 128 · see citing works
In vivo retention of <sup>18</sup> F-AV-1451 in corticobasal syndrome
Smith, R., Schöll, M., Widner, H., van Westen, D., Svenningsson, P., Hägerström, D., Ohlsson, T., Jögi, J., Nilsson, C., & Hansson, O. (2017) · Neurology · doi:10.1212/wnl.0000000000004264 · Cited by 117 · see citing works
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91 · see citing works
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83 · see citing works
Neuroinflammation predicts disease progression in progressive supranuclear palsy
Malpetti, M., Passamonti, L., Jones, P. S., Street, D., Rittman, T., Fryer, T. D., Hong, Y. T., Vàsquez Rodriguez, P., Bevan-Jones, W. R., Aigbirhio, F. I., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325549 · Cited by 85 · see citing works
[18F]‐THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy
Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00440 · Cited by 72 · see citing works
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59 · see citing works
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
Hansen, A. K., Brooks, D. J., & Borghammer, P. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1143-1 · Cited by 51 · see citing works
- Authors
- Cho, H., Choi, J. Y., Hwang, M. S., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H.
- Affiliations
- Yonsei University (KR)
- Corresponding author
- Lyoo, Chul Hyoung
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2016-11-03
- Volume
- 32
- Issue
- 1
- Pages
- 134-140
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2546563765
- Cited by
- 119
- References
- 23
- Citations by year
- 2025: 6 · 2024: 8 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 13 · 2019: 16 · 2018: 18 · 2017: 25 · 2016: 2
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Movement Disorders (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Research Foundation of Korea (NRF) (2015R1C1A2A01054507)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- progressive supranuclear palsy, 18F-AV-1451, tau PET imaging, Parkinson's disease, putamen, globus pallidus, subthalamic nucleus, dentate nucleus
- MeSH terms
- Aged, Carbolines, Cerebellar Nuclei, Female, Globus Pallidus, Humans, Male, Middle Aged, Parkinson Disease, Putamen, Supranuclear Palsy, Progressive, tau Proteins, Subthalamic Nucleus, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
